Periodic peritonitis. Present management and future prospects.
Thirty-three patients with periodic peritonitis were treated with colchicine for 863 patient-months of observation (average, 27 months). There is a personal optimum dose, and the daily requirement varies at 1 or 1.5 mg. All patients responded to treatment. Episodes were precipitated in all patients who stopped their medications. No side effects were noticed. Four normal full-term infants were born to patients taking colchicine during the study.
D000293:Adolescent; D000328:Adult; D002648:Child; D003078:Colchicine / Q000008:administration & dosage / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged
D003078:Colchicine